PMID- 25877347
OWN - NLM
STAT- MEDLINE
DCOM- 20150806
LR  - 20181113
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 35
IP  - 2
DP  - 2015 Apr
TI  - Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of 
      randomized placebo-controlled trials.
PG  - 169-175
LID - 10.1007/s11596-015-1406-5 [doi]
AB  - The aim of this study was to summarize the efficacy and tolerability of 
      rotigotine in the treatment of primary restless legs syndrome (RLS). PubMed, 
      EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were 
      searched for English-language randomized controlled trials (RCTs) that assessed 
      the effectiveness of rotigotine for RLS. The pooled mean change from baseline in 
      International RLS (IRLS) Study Group Rating Scalescore and relative risk (RR) of 
      response based on the Clinical Global Impression-Improvement (CGI-I) scale score 
      were applied to evaluate the outcomes. The pooled proportions of adverse events 
      (AEs) were also estimated. Six RCTs were included. The meta-analysis showed a 
      favorable effectiveness of rotigotine versus placebo on RLS [mean change on IRLS 
      score: mean difference (MD)=-4.80; 95% confidence interval (CI): -5.90 to -3.70; 
      P<0.00001 and RR of response on CGI-I was 2.19; 95% CI: 1.86 to 2.58, P<0.00001]. 
      The most common AEs were application site reactions, nausea, headache and 
      fatigue. In general, rotigotine was well-tolerated in patients with primary RLS. 
      Based on the findings from the meta-analysis, rotigotine was more significantly 
      efficacious in the treatment of RLS than placebo. Nevertheless, long-term studies 
      and more evidence of comparisons of rotigotine with other dopamine agonists are 
      needed.
FAU - Ding, Jun
AU  - Ding J
AD  - Department of Neurology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Fan, Wei
AU  - Fan W
AD  - Department of Breast Surgery, Hubei Cancer Hospital, Wuhan, 430079, China.
FAU - Chen, Hong-Hui
AU  - Chen HH
AD  - Wuhan First Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, 430022, China.
FAU - Yan, Peng
AU  - Yan P
AD  - Department of Neurology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Sun, Sheng-Gang
AU  - Sun SG
AD  - Department of Neurology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China.
FAU - Zheng, Jin
AU  - Zheng J
AD  - Department of Neurology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, 430022, China. 
      zhengjin.md@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20150416
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Placebos)
RN  - 0 (Tetrahydronaphthalenes)
RN  - 0 (Thiophenes)
RN  - 87T4T8BO2E (rotigotine)
SB  - IM
MH  - Humans
MH  - Placebos
MH  - Randomized Controlled Trials as Topic
MH  - Restless Legs Syndrome/*drug therapy
MH  - Tetrahydronaphthalenes/*therapeutic use
MH  - Thiophenes/*therapeutic use
EDAT- 2015/04/17 06:00
MHDA- 2015/08/08 06:00
CRDT- 2015/04/17 06:00
PHST- 2014/10/10 00:00 [received]
PHST- 2015/02/22 00:00 [revised]
PHST- 2015/04/17 06:00 [entrez]
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2015/08/08 06:00 [medline]
AID - 10.1007/s11596-015-1406-5 [pii]
AID - 10.1007/s11596-015-1406-5 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2015 Apr;35(2):169-175. doi: 
      10.1007/s11596-015-1406-5. Epub 2015 Apr 16.